Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Show more...
FAQ
Qlucore AB (publ) 今天的股價是多少?▼
NOVKAN.ST 目前價格為 SEK0.03 SEK,過去 24 小時下跌了 -43.95%。在圖表上更密切關注 Qlucore AB (publ) 股票的表現。
Qlucore AB (publ) 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Stockholm Exchange 交易所,Qlucore AB (publ) 的股票以代號 NOVKAN.ST 進行交易。
Qlucore AB (publ) 的市值是多少?▼
今天 Qlucore AB (publ) 的市值為 3.03M
Qlucore AB (publ) 去年的營收是多少?▼
Qlucore AB (publ) 去年的營收為 0SEK。
Qlucore AB (publ) 去年的淨利是多少?▼
NOVKAN.ST 去年的淨收益為 -136.72MSEK。
Qlucore AB (publ) 有多少名員工?▼
截至 September 04, 2026,公司共有 5 名員工。
Qlucore AB (publ) 位於哪個產業?▼
Qlucore AB (publ)從事於Other產業。
Qlucore AB (publ) 何時完成拆股?▼
Qlucore AB (publ) 最近沒有進行任何拆股。
Qlucore AB (publ) 的總部在哪裡?▼
Qlucore AB (publ) 的總部位於 瑞典 的 Solna。